Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON22050
NL-OMON22050Not yet recruitingNot Applicable

Pilot Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation from Donors after Cardiac Death.

Angion Biomedica Europe LimitedAngion Biomedica Corp.1050 Stewart AvenueGarden City, NY 115300 sites36 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
36
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

/A

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •1. Subjects must sign the informed consent document prior to performance of any study related procedure including the Screening procedure;
  • •2. Males and females ≥ 18 years of age;

Exclusion Criteria

  • •1. Mean arterial pressure <40 mmHg or cardiac index <1.8 L/min/m2;
  • •2. Requires emergency dialysis for reasons other than high plasma creatinine levels, e.g. severe fluid overload or severe metabolic abnormalities;

Investigators

Sponsor
Angion Biomedica Europe LimitedAngion Biomedica Corp.1050 Stewart AvenueGarden City, NY 11530

Similar Trials

Completed
Phase 2
Pilot Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation from Donors after Cardiac DeathDelayed graft function1002914910038365
NL-OMON39114Angion Biomedica Corp.18
Active, not recruiting
Phase 1
Exploratory Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation from Donors after Cardiac Death
EUCTR2010-019243-19-GBAngion Biomedica Corp.36
Withdrawn
Phase 2
Pilot Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation from Donors after Cardiac Death.
NL-OMON32550Angion Biomedica Corp.30
Active, not recruiting
Not Applicable
Exploratory Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation from Donors after Cardiac DeathPatients suffering from end-stage renal disease, receiving a donor kidney from donors after cardiac deathMedDRA version: 17.0Level: LLTClassification code 10014647Term: End stage renal failureSystem Organ Class: 100000004857
EUCTR2010-019243-19-ESAngion Biomedica Corp.36
Unknown
Phase 2
Study on Delayed Graft Function Using Paired KidneysDelayed Graft Function
NCT01561599Angion Biomedica Corp12